Skip to content

Trial · Interventional

CompletedPhase 2Registry data

The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery

Overview

Status
Completed
Phase
Phase 2
Enrollment
227 participants (actual)
Sponsor
Zhejiang University · Other
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

China

Start
1 Jun 2025
Primary completion
25 May 2026
Completion
2 Jun 2026
First posted
27 Apr 2025
Last update posted
20 Aug 2026
Conditions
Cervical Spinal Stenosis · Thoracic Spinal Stenosis · Lumbar Spinal Stenosis · Rotator Cuff Injury · Femoral Head Necrosis · Spinal Trauma · Knee Joint Injury

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202520262027
  1. Ph 2

    The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery

    NCT06945926

    1 Jun 2025 to 2 Jun 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Postoperative delirium is a delirium that occurs within 7 days after surgery or before hospital discharge. It has been shown that combined POD can increase the incidence of postoperative pulmonary infections, deep vein thrombosis and decubitus ulcers, and increase the incidence of disability and mortality. The incidence of postoperative delirium in geriatric orthopedics is high. Investigators conduct a prospective clinical study on geriatric orthopedic surgery patients to investigate the effect of oxytocin nasal spray on the prevention of postoperative delirium in geriatric orthopedic surgery. Cases were included according to the inclusion and exclusion criteria, and induction, maintenance and resuscitation were performed according to the standard protocol for general anesthesia. Before the end of surgery, the Investigators administered oxytocin nasal spray (Oxytocin) that was 3 sprays in each nostril (4 IU each) for a total of 24 IU. Beginning 1 day postoperatively, administer 24 IU of oxytocin nasal spray 2 times/day in the morning and in the evening. Until 7 days after surgery or discharge. The sample size are 77 cases in phase I and 143 cases in phase 2, total 220 cases.

Interventions

  • oxytocin nasal sprayDrug

Arms1

  • Experimental

    Oxytocin nasal spray given to geriatric orthopedic general anesthesia patients

    Cases were included according to the inclusion and exclusion criteria, and induction, maintenance and resuscitation were performed according to the standard protocol for general anesthesia.Before the end of anesthesia, the experimenter administered oxytocin nasal spray (Oxytocin) that was 3 sprays in each nostril (4 IU each) for a total of 24 IU. Beginning 1 day postoperatively, administer 24 IU of oxytocin nasal spray 2 times/day in the morning and 24 IU in the evening.Until 7 days after surgery or discharge.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Incidence of postoperative delirium within 7 days after surgery.

    Time frame · From the day of surgery to 7 days after surgery.Twice a day after surgery, once in the morning and once in the afternoon

    Registry description

    In the anesthesia recovery room, the CAM-ICU(The Confusion Assessment method for the ICU ) scale was performed 30 min after extubation. Postoperative delirium was measured by the 3D-CAM (The 3-Minute Diagnostic Confusion Assessment Method)scale from postoperative day 1 until postoperative day 7 or before discharge from the hospital. The CAM scale includes four major features: 1. Acute onset or fluctuating changes in condition 2. Inattention 3. Confusion 4. Changes in level of consciousness. Delirium is diagnosed when features 1 and 2 are positive at the same time, and/or features 3 and 4 are positive.

Secondary outcomes(2)
  1. The severity of postoperative delirium

    Time frame · From the day of surgery to 7 days after surgery

    Registry description

    If the patient develops delirium, assess the severity with the MDAS( Memory Disorder Assessment Scale).The total score is 30 points, and the higher the score, the greater the degree of delirium

  2. Length of hospitalization

    Time frame · 1 year

    Registry description

    Recording the duration of hospitalization,Time from admission to discharge

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies25

Studies that cite this trial.

Studies with results

14 studies on this page

Indexing hint: Systematic review · 2025

2 results

Oxytocin in old age psychiatry: A systematic review of the safety of using intranasal oxytocin in older adults.

Sawares et al. 2025Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatristscited by 4

PMID 39474844PMC11804147DOI 10.1177/10398562241291335PUB-39474844

Free to read · publisher termsCC BY-NC2 results

Indexing hint: Randomized controlled trial · 2024

4 results

Chronic oxytocin administration stimulates the oxytocinergic system in children with autism.

Moerkerke et al. 2024Nature communicationscited by 35

PMID 38167302PMC10762037DOI 10.1038/s41467-023-44334-4PUB-38167302

CC BY4 results

Indexing hint: Randomized controlled trial · 2021

3 results

Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder.

Sikich et al. 2021The New England journal of medicinecited by 211

PMID 34644471PMC9701092DOI 10.1056/nejmoa2103583PUB-34644471

Rights unknown3 results

Indexing hint: Randomized controlled trial · 2018

4 results

Effects of Intranasal Oxytocin on the Blood Oxygenation Level-Dependent Signal in Food Motivation and Cognitive Control Pathways in Overweight and Obese Men.

Plessow et al. 2018Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacologycited by 52

PMID 28930284PMC5770767DOI 10.1038/npp.2017.226PUB-28930284

Rights unknown4 results

Indexing hint: Randomized controlled trial · 2017

3 results

Intranasal Oxytocin to Prevent Posttraumatic Stress Disorder Symptoms: A Randomized Controlled Trial in Emergency Department Patients.

van Zuiden et al. 2017Biological psychiatrycited by 113

PMID 28087128DOI 10.1016/j.biopsych.2016.11.012PUB-28087128

Full text at the publisher3 results

Indexing hint: Meta-analysis (pooled) · 2017

5 results

Meta-analysis of the effects of intranasal oxytocin on interpretation and expression of emotions.

Leppanen et al. 2017Neuroscience and biobehavioral reviewscited by 141

PMID 28467893DOI 10.1016/j.neubiorev.2017.04.010PUB-28467893

Rights unknown5 results

Indexing hint: Meta-analysis (pooled) · 2017

4 results

Intranasal Oxytocin May Improve High-Level Social Cognition in Schizophrenia, But Not Social Cognition or Neurocognition in General: A Multilevel Bayesian Meta-analysis.

Bürkner et al. 2017Schizophrenia bulletincited by 59

PMID 28586471PMC5737621DOI 10.1093/schbul/sbx053PUB-28586471

Rights unknown4 results

Indexing hint: Randomized controlled trial · 2017

3 results

Kinetics and Dose Dependency of Intranasal Oxytocin Effects on Amygdala Reactivity.

Spengler et al. 2017Biological psychiatrycited by 206

PMID 28629540DOI 10.1016/j.biopsych.2017.04.015PUB-28629540

Full text at the publisher3 results

Indexing hint: Meta-analysis (pooled) · 2017

10 results

Neural substrates underlying the effects of oxytocin: a quantitative meta-analysis of pharmaco-imaging studies.

Wang et al. 2017Social cognitive and affective neurosciencecited by 74

PMID 29048602PMC5647800DOI 10.1093/scan/nsx085PUB-29048602

Free to read · publisher termsCC BY-NC10 results

Indexing hint: Randomized controlled trial · 2016

1 result

Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial.

Quintana et al. 2016Psychoneuroendocrinologycited by 87

PMID 27107209DOI 10.1016/j.psyneuen.2016.04.010PUB-27107209

Full text at the publisher1 result

Indexing hint: Meta-analysis (pooled) · 2013

5 results

The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: a meta-analysis.

Shahrestani et al. 2013Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacologycited by 218

PMID 23575742PMC3746698DOI 10.1038/npp.2013.86PUB-23575742

Rights unknown5 results

Indexing hint: Systematic review · 2011

3 results

A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research.

MacDonald et al. 2011Psychoneuroendocrinologycited by 276

PMID 21429671DOI 10.1016/j.psyneuen.2011.02.015PUB-21429671

Full text at the publisher3 results

Indexing hint: Randomized controlled trial · 2011

2 results

The effects of oxytocin on social cognition and behaviour in frontotemporal dementia.

Jesso et al. 2011Brain : a journal of neurologycited by 90

PMID 21859765DOI 10.1093/brain/awr171PUB-21859765

Rights unknown2 results

Indexing hint: Systematic review · 2010

1 result

The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans.

Macdonald et al. 2010Harvard review of psychiatrycited by 364

PMID 20047458DOI 10.3109/10673220903523615PUB-20047458

Full text at the publisher1 result

More studies

11 studies on this page

Indexing hint: Animal study · 2025

Interplay of MeCP2/REST/Synaptophysin-BDNF and intranasal oxytocin influence on Aβ-induced memory and cognitive impairments.

Sarahian et al. 2025Behavioural brain researchcited by 4

PMID 39236931DOI 10.1016/j.bbr.2024.115235PUB-39236931

Full text at the publisher
Publisher page

Indexing hint: Animal study · 2023

Oxytocin alleviates cognitive and memory impairments by decreasing hippocampal microglial activation and synaptic defects via OXTR/ERK/STAT3 pathway in a mouse model of sepsis-associated encephalopathy.

Jiang et al. 2023Brain, behavior, and immunitycited by 52

PMID 37648002DOI 10.1016/j.bbi.2023.08.023PUB-37648002

Full text at the publisher
Publisher page

Indexing hint: Animal study · 2020

Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques.

Lee et al. 2020Nature communicationscited by 109

PMID 32494001PMC7270110DOI 10.1038/s41467-020-15942-1PUB-32494001

CC BY
Download PDF

PubMed tag: none · 2019

Does peripherally administered oxytocin enter the brain? Compelling new evidence in a long-running debate.

Bowen et al. 2019Pharmacological researchcited by 18

PMID 31233803DOI 10.1016/j.phrs.2019.104325PUB-31233803

Full text at the publisher
Publisher page

Indexing hint: Animal study · 2019

Oxytocin delivered nasally or intraperitoneally reaches the brain and plasma of normal and oxytocin knockout mice.

Smith et al. 2019Pharmacological researchcited by 106

PMID 31238093PMC6679720DOI 10.1016/j.phrs.2019.104324PUB-31238093

Rights unknown
Source link

Indexing hint: Animal study · 2018

Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay.

Lee et al. 2018Molecular psychiatrycited by 200

PMID 28289281PMC5862033DOI 10.1038/mp.2017.27PUB-28289281

Rights unknown
Source link

Indexing hint: Review · 2018

Oxytocin and Pain Perception: From Animal Models to Human Research.

Boll et al. 2018Neurosciencecited by 97

PMID 28965836DOI 10.1016/j.neuroscience.2017.09.041PUB-28965836

Full text at the publisher
Publisher page

Indexing hint: Review · 2013

Ageing and oxytocin: a call for extending human oxytocin research to ageing populations--a mini-review.

Huffmeijer et al. 2013Gerontologycited by 57

PMID 22922544DOI 10.1159/000341333PUB-22922544

Rights unknown
Source link

PubMed tag: none · 2012

Inhaled oxytocin amplifies both vicarious reinforcement and self reinforcement in rhesus macaques (Macaca mulatta).

Chang et al. 2012Proceedings of the National Academy of Sciences of the United States of Americacited by 204

PMID 22215593PMC3271866DOI 10.1073/pnas.1114621109PUB-22215593

Rights unknown
Source link

Indexing hint: Review · 2011

Prosocial effects of oxytocin and clinical evidence for its therapeutic potential.

Striepens et al. 2011Frontiers in neuroendocrinologycited by 221

PMID 21802441DOI 10.1016/j.yfrne.2011.07.001PUB-21802441

Full text at the publisher
Publisher page

Indexing hint: Animal study · 2000

Brain uptake and the analgesic effect of oxytocin--its usefulness as an analgesic agent.

Kang et al. 2000Archives of pharmacal researchcited by 47

PMID 10976589DOI 10.1007/bf02975453PUB-10976589

Full text at the publisher
Publisher page

Eligibility

Who could join, as posted.

Sex
All
Age
from 65 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Elderly patients undergoing orthopedic surgery under general anesthesia Inclusion criteria: 1. Age ≥ 65 years; 2. Patients who were to undergo elective orthopedic surgery under general anesthesia with tracheal intubation; 3. ASA class I-III; 4. Estimated duration of surgery ≥ 1 hour; (5) The patient himself/herself or his/her legal representative; 5. Informed consent from the patient or legal representative; 6. Proficiency in the use of Chinese language for communication. Exclusion criteria: 1. Nasal cavity occupation, patients with fillers in the nose 2. Oxytocin allergy; 3. Patients with previous psychiatric and neurological disorders, such as depression, severe central nervous system depression, Parkinson's disease, basal ganglia disease. Goldson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis, and so on; 4. Pregnant and lactating women 5. Patients with severe hepatic insufficiency (Child-Pugh class C); 6. patients with severe renal insufficiency (dialysis is required before surgery) 7. Severe heart failure (METS\<4); 8. Preoperative inability to communicate (coma or dementia); 9. Severe preoperative blindness, deafness, or inability to understand Mandarin to complete preoperative delirium screening; 10. Preoperative cognitive impairment as determined by a MoCA evaluation prior to surgery; 11. Patients who are scheduled for 2 surgeries within 7 days of surgery; 12. Patients with bone malignancy 13. Currently participating in other clinical trials.

PepBank is a research reference. Talk to a doctor before you use any peptide.